The report describes that both boys had underlying and previously undiagnosed cardiac conditions. Given their overactive immune response to the vaccines, they would not have survived an infection with SARS-CoV-2, either. (And people want to take supplements to "boost" their immune function--to increase their chance of life-threatening cytokine storm, I presume.)
One cannot take a one in 1.48 million occurrence as evidence of general harm. What it means is that that one in 1.48 million individual has an unfortunate genetic heritage that makes their immune system respond atypically. And the one in 1.48 million death occurring in close proximity to vaccine administration is several orders of magnitude lower than the 1 death per 108 Covid cases.
Oh, and where I get the one in 1.48 million figure:
How many COVID-19 vaccines has Connecticut administered? (Updated May 10, 2023.) According to this, 2,967,081 people in Connecticut are considered fully vaccinated, meaning they have had two doses of vaccine. With two deaths occurring in temporal proximity to vaccine administration, the math comes out to one per 1.48 million.
Approximately 25% of the populati9n has a PFO or Patent Foramen Ovale. This is a hole between the right and left atrium that allows blood to bypass the lungs. Problem is, a PFO allows blood clots to bypass the lungs and go directly to the brain.
The 25% is an average, consisting of 30% rate in people who die young and 20% in the elderly.
Ordinarily, most people never know if they have a PFO.
Patent Foramen Ovale-associated Stroke and COVID-19 Vaccination
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311394/
COVID-19 infection has been associated with paradoxical thromboembolism through a patent foramen ovale (PFO) and ischaemic stroke. Such events have not been reported after COVID-19 vaccination. The aim of the present study was to investigate PFO-associated stroke during the mass COVID-19 vaccination in Slovenia.
Of the 28 patients presenting with PFO-associated stroke, 12 patients (42.9%) were vaccinated prior to the event, of whom nine were women and three were men, aged between 21 and 70 years. Stroke occurred within 35 days after vaccination in six patients (50%). Clinical presentation included motor dysphasia, paresis, vertigo, ataxia, paraesthesia, headache, diplopia and hemianopia. At hospital discharge, 11 patients (91.6%) had at least one residual ischaemic lesion. Conclusion: A temporal coincidence of COVID-19 vaccination and PFO-associated stroke has been described. A potential cause–effect relationship may only be hypothesised.
COVID-19 has been associated with coagulopathy with increased risk of venous thrombosis, which may, in the presence of PFO, lead to paradoxical embolism and ischaemic stroke.[5–9] Given that thrombotic events, including vaccine-induced immune thrombotic thrombocytopenia and formation of myocardial microthrombi, have been documented also after COVID-19 vaccines approved by the European Medicines Agency (EMA), we chose to investigate the occurrence of PFO-associated stroke during the mass COVID-19 vaccination in Slovenia.